Early stage medical device developer Tulavi Therapeutics has raised approximately $3 million in a new round of equity financing, according to recently posted SEC filings.
Tulavi Therapeutics is developing a medical device-based therapy intended to prevent or treat aberrant neural reflex arcs in peripheral and visceral disease. The technology is intended for use through both surgical and interventional approaches, according to the company’s website.
The company is being led by former Reflex Medical founder & CEO Corinne Bright.
Money in the round comes from three anonymous investors with the first sale dated on April 24 of this year, according to the filing.
The offering had a minimum investment of $159,999, according to the SEC filing. The company is looking to raise an additional $1 million to bring the total raised up to $4 million, according to the posting.